Drug safety assessment of oral formulations of ketoconazole

Bibliography

• Ketoconazole approved for systemic fungal infections. FDA Drug Bull. U.S. Food and Drug Administration 1981;11:18-19
   Google Scholar
• Cucé LC, Wroclawski EL, Sampaio SA. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole. Int J Dermatol 1980;19:405-8
   PubMed Web of Science ®Google Scholar
• Varkey B. Oral antifungal therapy. Current status of ketoconazole. Postgrad Med 1983;73:52-3
   PubMed Web of Science ®Google Scholar
• Sohn CA. Evaluation of ketoconazole. Clin Pharm 1982;1:217-24
   PubMedGoogle Scholar
• Thienpont D, Van Cutsem J, Van Gerven F, et al. Ketoconazole – a new broad spectrum orally active antimycotic. Experientia 1979;35:606-7
   PubMedGoogle Scholar
• Heeres J, Backx LJ, Mostmans JH, Van Cutsem J. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1979;22:1003-5
   PubMed Web of Science ®Google Scholar
• Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987;294:419-22
   PubMed Web of Science ®Google Scholar
• Stricker BH, Blok AP, Bronkhorst FB, et al. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 1986;3:399-406
   PubMed Web of Science ®Google Scholar
• DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981;19:1073-4
   PubMed Web of Science ®Google Scholar
• Craven PC. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1985;312:1061
   PubMed Web of Science ®Google Scholar
• D’Mello AP, D’Souza MJ, Bates TR. Pharmacokinetics of ketoconazole-antipyrine interaction. Lancet 1985;2:209-10
   PubMed Web of Science ®Google Scholar
• Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clin Pharm 1986;5:522-3
   PubMedGoogle Scholar
• Murphy E, Hannon D, Callaghan B. Ketoconazole–theophylline interaction. Ir Med J 1987;80:123-4
   PubMedGoogle Scholar
• European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole [Internet]. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/07/WC500146613.pdf [Cited 17 September 2014]
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Oral ketonconazole: do not prescribe or use for fungal infections - risk of liver injury outweighs benefits [Internet]. 2013. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON300403 [Cited 23 September 2014]
   Google Scholar
• European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. European Medicines Agency 2013;1-3
   Google Scholar
• U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013
   Google Scholar
• Health Canada. Health Canada Endorsed Important Safety Information on Ketoconazole [Internet]. Ketoconazole - Risk of Potentially Fatal Liver Toxicity - For Health Professionals. 2013. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34173a-eng.php [Cited 17 September 2014]
   Google Scholar
• Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(Suppl 1):S161-9
   PubMed Web of Science ®Google Scholar
• Borgers M, Van den Bossche H, De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am J Med 1983;74:2-8
   PubMedGoogle Scholar
• Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980;17:922-8
   PubMed Web of Science ®Google Scholar
• Rodriguez RJ, Acosta D. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995;96:83-92
   PubMed Web of Science ®Google Scholar
• Rodriguez RJ, Acosta D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997;117:123-31
   PubMed Web of Science ®Google Scholar
• Administration AGD of HTG. Oral ketoconazole (Nizoral) 200 mg tablets [Internet]. Available from: http://www.tga.gov.au/safety/alerts-medicine-oral-ketoconazole-131010.htm#.U0gmjfldWCk [Cited 11 April 2014]
   Google Scholar
• Negroni R, Robles AM, Arechavala A, et al. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis 1980;2:643-9
   PubMedGoogle Scholar
• Botter AA, Dethier F, Mertens RL, et al. Skin and nail mycoses: treatment with ketoconazole, a new oral antimycotic agent. Mykosen 1979;22:274-8
   PubMedGoogle Scholar
• Graybill JR, Herndon JH, Kniker WT, Levine HB. Ketoconazole treatment of chronic mucocutaneous candidiasis. Arch Dermatol 1980;116:1137-41
   PubMed Web of Science ®Google Scholar
• Restrepo A, Stevens DA, Gómez I, et al. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. Rev Infect Dis 1980;2:633-42
   PubMedGoogle Scholar
• Graybill JR, Lundberg D, Donovan W, et al. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis 1980;2:661-73
   PubMedGoogle Scholar
• Legendre R, Steltz M. A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. Rev Infect Dis 1980;2:586-91
   PubMedGoogle Scholar
• Borelli D. Treatment of pityriasis versicolor with ketoconazole. Rev Infect Dis 1980;2:592-5
   PubMedGoogle Scholar
• Welsh O, González JG, Diaz M, et al. Therapeutic evaluation of ketoconazole in patients with coccidioidomycosis. Rev Infect Dis 1980;2:651-5
   PubMedGoogle Scholar
• Jones HE, Simpson JG, Artis WM. Oral ketoconazole. An effective and safe treatment for dermatophytosis. Arch Dermatol 1981;117:129-34
   PubMed Web of Science ®Google Scholar
• Stevens DA, Stiller RL, Williams PL, Sugar AM. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med 1983;74:58-63
   PubMedGoogle Scholar
• Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142:2137-40
   PubMed Web of Science ®Google Scholar
• Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-8
   PubMed Web of Science ®Google Scholar
• Santen RJ, Van den Bossche H, Symoens J, et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983;57:732-6
   PubMed Web of Science ®Google Scholar
• Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144:2150-3
   PubMed Web of Science ®Google Scholar
• Pont A, Goldman ES, Sugar AM, et al. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985;145:1429-31
   PubMed Web of Science ®Google Scholar
• Petersen EA, Alling DW, Kirkpatrick CH. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med 1980;93:791-5
   PubMed Web of Science ®Google Scholar
• Heiberg JK, Svejgaard E. Toxic hepatis during ketoconazole treatment. Br Med J (Clin Res Ed) 1981;283:825-6
   PubMed Web of Science ®Google Scholar
• Macnair A, Gascoigne E, Heap J, et al. Hepatitis and ketoconazole therapy. BMJ 1981;283:1058
   PubMed Web of Science ®Google Scholar
• Firebrace D. Hepatitis and ketoconazole therapy. BMJ 1981;283:1058-9
   PubMed Web of Science ®Google Scholar
• Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983;74:80-5
   PubMedGoogle Scholar
• Yan JY, Nie XL, Tao QM, et al. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. Biomed Environ Sci 2013;26:605-10
   PubMed Web of Science ®Google Scholar
• Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009;15:2817-33
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. Nizoral Tablets Product Information [Internet]. 2011. Available from: http://www.janssen.com.au/files/Products/Nizoral_PI.pdf [Cited 17 September 2014]
   Google Scholar
• Janssen Pharmaceuticals, Inc. SPORANOX (itraconazole) Capsules Product Information [Internet]. 2013. Available from: https://www.janssen.com.au/files/Products/SPORANOX_CAPSULES_PI.pdf [Cited 17 September 2014]
   Google Scholar
• Pfizer Canada, Inc. DIFLUCAN 150* Fluconazole Capsule 150 mg Product Monograph [Internet]. 2010. Available from: http://www.pfizer.ca/en/our_products/products/monograph/178 [Cited 17 September 2014]
   Google Scholar
• Pfizer Canada, Inc. VFEND (voriconazole) Tablets 50 mg and 200 mg For Injection 200 mg/ Vial (10 mg/mL when reconstituted) Powder for Oral Suspension 3 g/ bottle (40 mg/mL when reconstituted) Product Monograph [Internet]. 2013. Available from: http://www.pfizer.ca/en/our_products/products/monograph/140 [Cited 17 September 2014]
   Google Scholar
• Novartis Pharmaceuticals Corp. Lamisil Prescribing Information [Internet]. 2013. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Lamisil_tablets.pdf
   Google Scholar
• Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52
   PubMed Web of Science ®Google Scholar
• Kao W-Y, Su C-W, Huang Y-S, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 2014;77:180-9
   PubMed Web of Science ®Google Scholar
• Von Moltke L, Greenblatt D, Duan S, et al. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in-vitro. Pharm Pharmacol Commun 1998;4:443-5
   Google Scholar
• Girois SB, Chapuis F, Decullier E, Revol BGP. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2006;25:138-49
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US, Inc. AmBisome (amphotericin B) liposome for injection [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf [Cited 23 October 2014]
   Google Scholar
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009;7:981-98
   PubMed Web of Science ®Google Scholar
• Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41
   PubMed Web of Science ®Google Scholar
• Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010;54:2409-19
   PubMed Web of Science ®Google Scholar
• Zhang C, Cheng J, Jiang Y, Liu J. Application of caspofungin in China compared with amphotericin B and fluconazole. Ther Clin Risk Manag 2014;10:737-41
   PubMed Web of Science ®Google Scholar
• Marques SA. Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. An Bras Dermatol 2013;88:700-11
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Rendon A, et al. Coccidioidomycosis. Clin Dermatol 2012;30:573-91
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US, Inc. MYCAMINE (micafungin sodium) for injection [Internet]. 2013; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021506s015lbl.pdf
   Google Scholar
• Merck & Co., Inc. CANCIDAS (caspofungin acetate) for injection [Internet]. 2013. Available from: http://www.merck.ca/assets/en/pdf/products/cancidas-pm_e.pdf [Cited 24 October 2013]
   Google Scholar
• Vicuron Pharmaceuticals. ERAXIS (Anidulafungin) for injection [Internet]. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021632s000,021948s000lbl.pdf [Cited 24 October 2013]
   Google Scholar
• Gupta AK, Daigle D, Paquet M. Therapies for onychomycosis: a systematic review and network meta-analysis of mycological cure. J Am Podiatr Med Assoc 2014. [ Epub ahead of print]
   Google Scholar
• Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 1987;6:46-9
   PubMed Web of Science ®Google Scholar
• Tanz RR, Hebert AA, Esterly NB. Treating tinea capitis: should ketoconazole replace griseofulvin? J Pediatr 1988;112:987-91
   PubMed Web of Science ®Google Scholar
• Shemer A, Nathansohn N, Kaplan B, Trau H. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 1999;10:19-23
   Web of Science ®Google Scholar
• Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002;13:73-6
   PubMed Web of Science ®Google Scholar
• Yazdanpanah MJ, Azizi H, Suizi B. Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor. Mycoses 2007;50:311-13
   PubMed Web of Science ®Google Scholar
• Bhogal CS, Singal A, Baruah MC. Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study. J Dermatol 2001;28:535-9
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-15
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30:677-98; quiz 698–700
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33; quiz 934–6
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Noxafil® (posaconazole) [Internet]. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205596s000lbl.pdf [Cited 24 October 2014]
   Google Scholar